在当今肿瘤治疗领域，新型抗肿瘤药物中的「靶向治疗药物」与「免疫检查点抑制剂」堪称闪亮双子星。靶向治疗药物需通过基因检测明确敏感靶点，从而实现精准施治；而免疫检查点抑制剂虽尚未形成统一的生物标志物评估标准，但 PD-L1 高表达通常预示着更优的治疗反应 ...

Accordingly, targeting EGFR has been intensely pursued, with the development of a series of promising molecular inhibitors for use in clinical oncology. As is common in cancer therapy, challenges ...

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in ...

The optimal selection of patients with non-small-cell lung cancer (NSCLC) for treatment with oral small-molecule tyrosine kinase inhibitors (TKIs) has been an area of great debate. Inhibiting EGFR ...

Researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry have divulged EGFR (L858R/T790M/C797S triple mutant) and ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced the upcoming presentation of the ...

EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization's updated clinical practice guideline. In a synopsis of the recently ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared ...

For example, EGFR 19 deletions and EGFR L858R point mutations respond well to tyrosine kinase inhibitors (TKIs), which are also called EGFR inhibitors. Drugs that target the EGFR protein and block ...

Patients with lung adenocarcinoma typically carry a mutation in the Epidermal Growth Factor Receptor (EGFR) gene, making them ...